TherapeuticsMD (TXMD) Receives Price Target

TherapeuticsMD (TXMD) : The highest level TherapeuticsMD (TXMD) is projected to reach is $18 for the short term and the lowest estimate is at $13. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $15.63 and the possibility the share price can swing is $2.5.

TherapeuticsMD (TXMD) : The consensus on TherapeuticsMD (TXMD) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.


TherapeuticsMD (NYSEMKT:TXMD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.01 and $6.84 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.03, notching a gain of 2.18% for the day. The total traded volume was 1,020,378 . The stock had closed at $6.88 on the previous day.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.